Stay updated on Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.4.3; no visible changes to study content.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedA new site revision label Revision: v3.4.2 appears and a prior government-funding status notice is removed. These are general site-wide UI updates and do not affect the study details or eligibility criteria.SummaryDifference0.4%

- Check41 days agoChange DetectedA system notice about government funding lapse and NIH Clinical Center status was added, and the site revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded glossary toggle to the study page and updated metadata labels (including 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'), with slight wording/capitalization adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision metadata updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedLocations now include Massachusetts; HHS Vulnerability Disclosure and Massachusetts Locations sections were removed.SummaryDifference0.2%

Stay in the know with updates to Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.